May your vials stay cold, your peptides stay potent, and your protocols stay effective.
8.6 Renal Impairment JANUMET JANUMET is not recommended in patients with an eGFR between 30 and less than 45 mL/min/1.73 m2 because these patients require a lower dosage of sitagliptin than what is available in the fixed dose combination JANUMET product
The mean dose of glipizide after the titration period was 10 mg
Multi-Pathway Approach to Weight Management Unlike single- or dual-agonist compounds, retatrutide targets three complementary metabolic pathways at once
Drug manufacturer Novo Nordisk produces it under the brand name Rybelsus, and the FDA approved it for managing blood glucose in people with Type 2 diabetes but not Type 1 diabetes
You might also feel numbness or tingling in the hands and feet , have trouble walking, or notice changes in thinking